BetaGlue Therapeutics

BetaGlue Therapeutics is a biotech company in Milan, Italy, founded in 2017. It has raised $18.7M across 2 rounds, most recently a $7.0M Corporate Round in December 2024.

YntraDose brings radiotherapy directly and only to the tumor

Headquarters
Milan
Founded
2017
Business Model
B2B
Total Funding
$18.7M
Last Round
$7.0M Corporate RoundDec 2024
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 2 investors for this company. The full record is or through the API.

About

BetaGlue Therapeutics is pioneering targeted nuclear therapies for solid tumours by combining biotechnology, nuclear science, and interventional oncology to deliver precision radiotherapeutics directly to the tumor. Its lead solution, YntraDose, is a Yttrium-90 microsphere radiotherapy platform designed for localized, personalized treatment of solid tumours, beginning with pancreatic cancer. The company aims for YntraDose to become a new standard of care by offering an easy-to-use interventional oncology option across pancreatic, liver, breast, and other solid-tumor patient populations.

Summary

It has raised $18.7M in total across 2 rounds, most recently a $7.0M Corporate Round in Dec 2024. Investors include Innogest Capital and Panakes Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Corporate RoundENEA-Tech Biomedical InvestmentDec 2024
$7.0M

Sign up to see all 2 events

Funding: Corporate Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Avenzo

Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...

San Diego, United States1–10Biotech, Oncology
Series BTotal funding$832.0MSep 2025
Bicycle TherapeuticsIPO

Novel bicyclic peptides and drug conjugates for cancer

Cambridge, United States201–500Biotech, Oncology
Private EquityTotal funding$607.0MJan 2024
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

BetaGlue Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/betaglue-therapeutics"><img src="https://indexed.vc/api/badge/company/betaglue-therapeutics" alt="BetaGlue Therapeutics on Indexed.vc" width="260" height="76" /></a>